Featuring market attractiveness scoring, total addressable market sizing, company benchmarking matrices, interactive Excel dashboards, deeper supply chain intelligence, emerging startup tracking, and granular product-level insights, The Business Research Company’s 2026 market reports are built to deliver research that is both more actionable and more strategically valuable.
Inflectra Market Size And Revenue Outlook Through 2030
Historical growth was fueled by the elevated costs of originator TNF inhibitors, alongside regulatory approvals for biosimilars, an escalating burden of autoimmune diseases, the adoption within hospital formularies, and various cost containment strategies employed by payers.
Anticipated expansion during the forecast period is fueled by supportive regulatory environments for biosimilars, broader patient access to biologic treatments, an increase in inflammatory disease cases, intense competitive pricing pressures, and greater physician understanding. Key developments expected over the same timeframe encompass the growing uptake of biosimilar products, cost-motivated transitions from original biologics, the broadening of treatment options for autoimmune diseases, enhanced physician confidence in the safety of biosimilars, and procurement efforts for biosimilars primarily led by hospitals.
Get A Free Sample Report With In-Depth Market Insights:
Inflectra Market Expansion Drivers: What’s Shaping Future Growth?
The rising incidence of autoimmune conditions is projected to boost the expansion of the inflectra market in the coming years. Autoimmune diseases involve the immune system erroneously attacking healthy cells, resulting in inflammation and harm to various tissues and organs. Factors contributing to the widespread occurrence of autoimmune diseases include shifts in diet, exposure to contaminants, specific lifestyle habits, and climate change. These diseases influence the inflectra market by escalating the need for efficient treatment alternatives, as a greater number of patients seek therapies like inflectra, which is vital for managing ailments such as rheumatoid arthritis and Crohn’s disease through its action of blocking tumor necrosis factor-alpha (TNF-α) to reduce inflammation. For example, in September 2023, the IBD Clinical and Research Centre, a Canada-based organization dedicated to enhancing the lives of patients with Crohn’s disease and ulcerative colitis, reported that over 320,000 Canadians lived with inflammatory bowel disease (IBD) in 2023, showing a prevalence of 825 per 100,000. With this prevalence increasing by 2.44% annually, it is anticipated that 1.1% of Canada’s population, equivalent to 470,000 people, will suffer from IBD by 2035. Consequently, the growing prevalence of autoimmune diseases is fueling the development of the inflectra market. The increasing volume of clinical trials is anticipated to stimulate the expansion of the inflectra market in the future. Clinical trials are investigative studies that engage human subjects to assess the effects of novel medical interventions, such as medications, devices, and behavioral therapies, on health results; they are crucial for establishing the safety and effectiveness of these interventions prior to their approval for broad clinical application. The rise in clinical trials stems from an escalating need for cutting-edge treatments and therapies, fueled by breakthroughs in medical research, the imperative for varied participant representation, and the urgency to address critical medical needs across diverse populations. The proliferation of clinical trials influences inflectra by producing compelling data regarding its efficacy and safety, thereby strengthening its market standing and boosting its appeal as a therapeutic choice for autoimmune conditions. For example, in April 2025, a report from the National Library of Medicine, a US-based government agency, indicated that as of March 2025, ClinicalTrials.gov featured 404,637 interventional clinical trials, with 27,751 new trials initiated in 2023. Thus, the expanding number of clinical trials is propelling the growth of the inflectra market.
Inflectra Market Segment Landscape: Which Areas Lead Development?
The inflectra market covered in this report is segmented –
1) By Patient Demographics: Pediatric Patients, Adult Patients
2) By Application: Rheumatoid Arthritis, Crohn’s Disease, Ulcerative Colitis, Ankylosing Spondylitis, Psoriatic Arthritis, Other Indications
3) By Distribution Channel: Hospitals, Specialty Clinics, Online Pharmacies, Retail Pharmacies
Inflectra Market Strategic Trends: What Defines The Next Growth Phase?
A significant trend in the inflectra market involves focusing on the development of innovative products, such as subcutaneous infliximab biosimilars. The goal is to offer a convenient and effective maintenance treatment solution for patients with inflammatory bowel disease through a subcutaneous formulation. A subcutaneous infliximab biosimilar is an injectable form of infliximab, providing a more accessible administration method for treating autoimmune diseases. For instance, in October 2023, Celltrion USA, a US-based subsidiary of the biopharmaceutical company Celltrion, announced that the FDA had approved ZYMFENTRA (infliximab-dyyb). This product is the first and only subcutaneous formulation of infliximab for the maintenance treatment of moderately to severely active Crohn’s disease (CD) and ulcerative colitis (UC) in adults. This innovative subcutaneous formulation ensures stable elevated serum infliximab levels, offering a more convenient and flexible administration option for both patients and healthcare providers. The approval is notable as it addresses the everyday burden of managing inflammatory bowel disease and enhances patient control over their treatment regimen.
Inflectra Market Industry Leaders And Competitive Landscape
Major companies operating in the inflectra market are Celltrion Inc
View The Full Inflectra Market Report:
Inflectra Market Largest Region: Which Geography Holds The Biggest Share?
Europe was the largest region in the inflectra market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the inflectra market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Reach Out To Our Team:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
